Timber Creek Capital Management buys $3.5 Million stake in Amgen (AMGN)

Amgen (AMGN) : Timber Creek Capital Management scooped up 2,030 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 11, 2016. The investment management firm now holds a total of 23,059 shares of Amgen which is valued at $3.5 Million.Amgen makes up approximately 3.14% of Timber Creek Capital Management’s portfolio.

Other Hedge Funds, Including , Texan Capital Management sold out all of its stake in AMGN during the most recent quarter. The investment firm sold 23,063 shares of AMGN which is valued $3.5 Million. Richard Bernstein Advisors sold out all of its stake in AMGN during the most recent quarter. The investment firm sold 41,689 shares of AMGN which is valued $6.4 Million.Motco boosted its stake in AMGN in the latest quarter, The investment management firm added 258 additional shares and now holds a total of 517 shares of Amgen which is valued at $79,199. Amgen makes up approx 0.01% of Motco’s portfolio. David R. Rahn Associates added AMGN to its portfolio by purchasing 3,144 company shares during the most recent quarter which is valued at $481,629. Amgen makes up approx 0.39% of David R. Rahn Associates’s portfolio.Flossbach Von Storch Ag boosted its stake in AMGN in the latest quarter, The investment management firm added 296,850 additional shares and now holds a total of 1,179,732 shares of Amgen which is valued at $180.7 Million. Amgen makes up approx 2.99% of Flossbach Von Storch Ag’s portfolio.

Amgen opened for trading at $152.35 and hit $153.86 on the upside on Monday, eventually ending the session at $153.27, with a gain of 0.60% or 0.92 points. The heightened volatility saw the trading volume jump to 24,15,093 shares. Company has a market cap of $115,139 M.

On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.

Many Wall Street Analysts have commented on Amgen. Citigroup Initiated Amgen on Feb 25, 2016 to “Neutral”, Price Target of the shares are set at $165.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.